[{"id":"d794956d-7d72-4864-b172-3cc363bc86b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06649331","created_at":"2025-02-26T09:16:39.825Z","updated_at":"2025-02-26T09:16:39.825Z","phase":"Phase 2","brief_title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","source_id_and_acronym":"NCT06649331","lead_sponsor":"Fudan University","biomarkers":" HER-2 • NECTIN4 • TACSTD2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • NECTIN4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • ruzaltatug rezetecan (SHR-A2009) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/21/2024","start_date":" 10/21/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-12-10"}]